Suppr超能文献

相似文献

1
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Arthritis Res Ther. 2008;10(1):R14. doi: 10.1186/ar2365. Epub 2008 Jan 30.
2
Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
Int Immunopharmacol. 2019 Dec;77:105914. doi: 10.1016/j.intimp.2019.105914. Epub 2019 Oct 18.
4
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Mol Pharm. 2018 Aug 6;15(8):3456-3467. doi: 10.1021/acs.molpharmaceut.8b00433. Epub 2018 Jul 16.
6
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.
7
Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
J Pharmacol Exp Ther. 2014 Feb;348(2):271-80. doi: 10.1124/jpet.113.205955. Epub 2013 Nov 15.
8
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
Arch Pharm (Weinheim). 2017 Nov;350(11). doi: 10.1002/ardp.201700194. Epub 2017 Sep 25.
9
Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse.
Clin Immunol. 2006 Jul;120(1):57-67. doi: 10.1016/j.clim.2006.03.005. Epub 2006 May 2.
10
Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Arthritis Res Ther. 2015 Dec 10;17:356. doi: 10.1186/s13075-015-0866-0.

引用本文的文献

2
Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.
JCI Insight. 2025 Feb 27;10(7):e187921. doi: 10.1172/jci.insight.187921.
3
Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model.
Drug Deliv Transl Res. 2024 Nov 11. doi: 10.1007/s13346-024-01736-1.
4
Clinical Scoring of Disease Activity in Animal Models.
Methods Mol Biol. 2024;2766:37-42. doi: 10.1007/978-1-0716-3682-4_6.
5
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Ann Rheum Dis. 2024 Jan 11;83(2):139-160. doi: 10.1136/ard-2023-223850.
6
Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease.
Int J Mol Sci. 2023 Sep 25;24(19):14509. doi: 10.3390/ijms241914509.
7
Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes.
Open Access Rheumatol. 2022 Oct 4;14:195-209. doi: 10.2147/OARRR.S363736. eCollection 2022.
8
Tofacitinib Suppresses Natural Killer Cells and : Implications for Amyotrophic Lateral Sclerosis.
Front Immunol. 2022 Feb 7;13:773288. doi: 10.3389/fimmu.2022.773288. eCollection 2022.
9
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.
Arthritis Res Ther. 2021 Aug 14;23(1):213. doi: 10.1186/s13075-021-02587-8.
10
Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis.
J Inflamm Res. 2021 May 21;14:2133-2147. doi: 10.2147/JIR.S301076. eCollection 2021.

本文引用的文献

1
Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
J Med Chem. 2007 Nov 15;50(23):5712-9. doi: 10.1021/jm0611915. Epub 2007 Oct 19.
2
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
Nature. 2007 Jul 26;448(7152):480-3. doi: 10.1038/nature05969. Epub 2007 Jun 20.
3
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.
Nature. 2007 Jul 26;448(7152):484-487. doi: 10.1038/nature05970. Epub 2007 Jun 20.
4
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
Curr Opin Rheumatol. 2007 May;19(3):238-45. doi: 10.1097/BOR.0b013e328099af80.
6
The in vivo contribution of hematopoietic cells to systemic TNF and IL-6 production during endotoxemia.
Cytokine. 2006 Nov;36(3-4):160-6. doi: 10.1016/j.cyto.2006.11.010. Epub 2007 Jan 4.
7
Interleukin-7 induced immunopathology in arthritis.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii69-74. doi: 10.1136/ard.2006.058479.
8
Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis.
Scand J Immunol. 2006 Nov;64(5):515-22. doi: 10.1111/j.1365-3083.2006.01795.x.
9
Interleukin-6: a new therapeutic target.
Arthritis Res Ther. 2006;8 Suppl 2(Suppl 2):S5. doi: 10.1186/ar1969. Epub 2006 Jul 28.
10
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Ann Rheum Dis. 2006 Dec;65(12):1558-64. doi: 10.1136/ard.2005.050385. Epub 2006 Jun 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验